The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日新規
2026/08/31
2026年8月31日
13%
2026年12月31日
52%
$2,649 Vol.
2026年8月31日
$943 Vol.
13%
2026年12月31日
$1,706 Vol.
52%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
マーケット開始日： Jun 22, 2026, 10:10 PM ET
音量
$2,649終了日
2026/12/31マーケット開始日
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
音量
$2,649終了日
2026/12/31マーケット開始日
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA’s July 2026 Pharmacy Compounding Advisory Committee vote (8-6 with one abstention) to recommend BPC-157 for the Section 503A bulks list marked the clearest recent catalyst, overriding staff concerns over immunogenicity and impurities. BPC-157 had been removed from Category 2 in April 2026 after nomination withdrawals, shifting it into regulatory review without immediate compounding authorization. Actual placement on Category 1 requires formal notice-and-comment rulemaking, a process that historically spans eight to twelve months and remains subject to FDA leadership discretion. No final rule has issued as of mid-August 2026. Traders are therefore weighing the panel’s narrow endorsement against the uncertain timeline and possibility of further procedural delays or reversals before any firm Category 1 listing.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問